The National Human Genome Research Institute (NHGRI), through its Human Genome Research program (CFDA 93.172), has awarded a $352,929 Project Grant to Ribo-Therapeutics LLC to develop and validate a novel platform for the enrichment and profiling of circular RNAs (circRNAs). The goal is to create a "quick, robust, and unbiased" technology for isolating and characterizing the full repertoire of circRNAs, which have been implicated in various diseases but are challenging to study with current methods. The project, spanning August 2023 to May 2024, aims to establish the new "QUICK-circRNA" platform and compare its efficacy to existing circRNA isolation approaches across different cellular conditions. If successful, this work will provide an efficient and reproducible technology for advancing circRNA research and its applications in understanding human health and disease.
Generated 7/16/24, 6:51 AM